![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 17, 2015 8:20:24 AM
St. Helier, Jersey – Nov. 17, 2015 – Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning at 4:30 p.m. EST to discuss the new EF-14 analyses and Tumor Treating Fields (TTFields) presentations from the 20th Annual Meeting of the Society of Neuro-Oncology.
The new EF-14 clinical trial analyses to be presented at SNO and that will be discussed during the webcast show the use of TTFields therapy with temozolomide did not adversely affect newly diagnosed GBM patients’ quality of life; and, GBM patients who continued TTFields therapy in combination with chemotherapy, including bevacizumab, at first recurrence lived longer than patients who received chemotherapy alone.
Analysts and investors can participate in the conference call by dialing (877)726-5929 for domestic callers and (530)379-4648 for international callers, using the conference ID 81604390. Access the webcast live from the Investor Relations page of Novocure’s website, where it will be available for replay for 14 days following the call.
http://www.novocure.com/news-and-events/news/2015/11-17-2015.aspx
My Posts are my opinion protected by my first amendment right to free speech
You don't drown by falling in the water; you drown by staying there.
Recent NVCR News
- Novocure to Report Second Quarter 2024 Financial Results • Business Wire • 07/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:09:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:37:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:13:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:43:31 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival • Business Wire • 06/03/2024 12:00:00 PM
- TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland • Business Wire • 05/24/2024 01:06:00 PM
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany • Business Wire • 05/23/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:01:17 PM
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon • Business Wire • 05/02/2024 11:01:00 AM
- Novocure Reports First Quarter 2024 Financial Results • Business Wire • 05/02/2024 11:00:00 AM
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 • Business Wire • 04/24/2024 02:45:00 PM
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 • Business Wire • 04/05/2024 11:00:00 AM
- Novocure to Report First Quarter 2024 Financial Results • Business Wire • 04/01/2024 11:00:00 AM
- METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長 • Business Wire • 03/29/2024 12:07:00 AM
- Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs • Business Wire • 03/28/2024 05:51:00 PM
- L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives.. • Business Wire • 03/28/2024 05:50:00 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer • Business Wire • 03/27/2024 11:00:00 AM
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO • Business Wire • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:08:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:39:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:56:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:06:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:43:29 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM